Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Read more about Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Read more about KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer.
1st International Lung Cancer Conference in Beijing, October 27-30, 2002. Read more about 1st International Lung Cancer Conference in Beijing, October 27-30, 2002.
Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Read more about Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells.
Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433. Read more about Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433.
